BioNTech said it will close multiple manufacturing plants in Germany after failing to find buyers for the facilities. The move affects sites in Idar-Oberstein, Marburg, and Tübingen, and BioNTech cited capacity no longer needed following COVID vaccine demand declines and changes in responsibility for Comirnaty production in the coming years. BioNTech has already been consolidating capabilities after acquiring CureVac’s Tübingen plant, and the latest decision sharpens the operational cleanup of mRNA manufacturing footprint. The company estimates impact on about 1,860 jobs when including additional planned closures. For the broader mRNA manufacturing ecosystem, the actions underscore how rapidly vaccine capacity utilization can deteriorate, forcing a restructuring of specialized production networks.